{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:05:41Z","timestamp":1790928341712,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03241-8","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:50:38Z","timestamp":1762249838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease"],"prefix":"10.1186","volume":"30","author":[{"given":"Yanni","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nairong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"1","key":"3241_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"M Abdul Basith Khan","year":"2020","unstructured":"Abdul Basith Khan M, et al. Epidemiology of type 2 diabetes\u2014global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107\u201311.","journal-title":"J Epidemiol Glob Health"},{"key":"3241_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1161521","volume":"14","author":"R Ruze","year":"2023","unstructured":"Ruze R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521.","journal-title":"Front Endocrinol"},{"key":"3241_CR3","volume-title":"IDF Diabetes Atlas, 7th edn","author":"D Atlas","year":"2015","unstructured":"Atlas D, International diabetes federation, Atlas D. IDF Diabetes Atlas, 7th edn, vol. Vol. 33. Brussels: International Diabetes Federation; 2015."},{"issue":"2","key":"3241_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"7258","key":"3241_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312.","journal-title":"BMJ"},{"key":"3241_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:1\u201319.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3241_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12933-021-01417-0","volume":"20","author":"JFK Saraiva","year":"2021","unstructured":"Saraiva JFK, Franco D. Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol. 2021;20(1):235.","journal-title":"Cardiovasc Diabetol"},{"issue":"21","key":"3241_CR8","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1001\/jama.2019.17379","volume":"322","author":"RG Nelson","year":"2019","unstructured":"Nelson RG, et al. Development of risk prediction equations for incident chronic kidney disease. JAMA. 2019;322(21):2104\u201314.","journal-title":"JAMA"},{"issue":"2","key":"3241_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"3241_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"Consortium, G.C.R.","year":"2023","unstructured":"Consortium, G.C.R. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273\u201385.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3241_CR11","first-page":"S140","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023. Diabetes Care. 2022;46(Suppl 1):S140.","journal-title":"Diabetes Care"},{"issue":"11","key":"3241_CR12","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873\u201388.","journal-title":"Diabetes Care"},{"issue":"6","key":"3241_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","volume":"147","author":"S Bolen","year":"2007","unstructured":"Bolen S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386\u201399.","journal-title":"Ann Intern Med"},{"key":"3241_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645617","volume":"12","author":"JJ Meier","year":"2021","unstructured":"Meier JJ. Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol. 2021;12:645617.","journal-title":"Front Endocrinol"},{"issue":"19","key":"3241_CR15","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"key":"3241_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110605","volume":"198","author":"A Li","year":"2023","unstructured":"Li A, et al. Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2023;198:110605.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"3241_CR17","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1111\/dom.13361","volume":"20","author":"P Andreadis","year":"2018","unstructured":"Andreadis P, et al. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(9):2255\u201363.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"3241_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102511","volume":"16","author":"MS Zaazouee","year":"2022","unstructured":"Zaazouee MS, et al. Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes Metab Syndr. 2022;16(6):102511.","journal-title":"Diabetes Metab Syndr"},{"issue":"9","key":"3241_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"9","key":"3241_CR20","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","volume":"38","author":"P Rossing","year":"2023","unstructured":"Rossing P, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38(9):2041\u201351.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"3241_CR21","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s13300-024-01594-7","volume":"15","author":"S Xiong","year":"2024","unstructured":"Xiong S, et al. Adverse events of oral GLP-1 receptor agonist (semaglutide tablets): a real-world study based on FAERS from 2019 to 2023. Diabetes Ther. 2024;15(8):1717\u201333.","journal-title":"Diabetes Ther"},{"key":"3241_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01183-5","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:1\u201311.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"3241_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.pedhc.2021.04.011","volume":"35","author":"MK Swartz","year":"2021","unstructured":"Swartz MK. PRISMA 2020: an update. J Pediatr Health Care. 2021;35(4):351.","journal-title":"J Pediatr Health Care"},{"key":"3241_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"3241_CR25","first-page":"1","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"J Peterson","year":"2011","unstructured":"Peterson J, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, vol. 2. Ottawa: Ottawa Hospital Research Institute; 2011. p. 1\u201312."},{"key":"3241_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"3241_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1099451","author":"CC Berra","year":"2023","unstructured":"Berra CC, et al. Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: a retrospective, cohort study (Sema-MiDiab01). Front Endocrinol. 2023. https:\/\/doi.org\/10.3389\/fendo.2022.1099451.","journal-title":"Front Endocrinol"},{"issue":"8","key":"3241_CR28","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/ckj\/sfac096","volume":"15","author":"BA Bueno","year":"2022","unstructured":"Bueno BA, et al. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice. Clin Kidney J. 2022;15(8):1593\u2013600.","journal-title":"Clin Kidney J"},{"issue":"3","key":"3241_CR29","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/dom.15396","volume":"26","author":"O Kobo","year":"2024","unstructured":"Kobo O, et al. Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: a post hoc analysis. Diabetes Obes Metab. 2024;26(3):1129\u201332.","journal-title":"Diabetes Obes Metab"},{"key":"3241_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae613","author":"KW Mahaffey","year":"2024","unstructured":"Mahaffey KW, et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae613.","journal-title":"Eur Heart J"},{"issue":"10","key":"3241_CR31","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann JFE, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849\u201356.","journal-title":"Nat Med"},{"key":"3241_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164752","author":"P Pantanetti","year":"2024","unstructured":"Pantanetti P, et al. Oral semaglutide in type 2 diabetes: clinical-metabolic outcomes and quality of life in real-world practice. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13164752.","journal-title":"J Clin Med"},{"key":"3241_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.851035","author":"LM Perez-Belmonte","year":"2022","unstructured":"Perez-Belmonte LM, et al. Efficacy and safety of semaglutide for the management of obese patients with type 2 diabetes and chronic heart failure in real-world clinical practice. Front Endocrinol. 2022. https:\/\/doi.org\/10.3389\/fendo.2022.851035.","journal-title":"Front Endocrinol"},{"issue":"2","key":"3241_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"17","key":"3241_CR35","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","volume":"84","author":"RE Pratley","year":"2024","unstructured":"Pratley RE, et al. Effects of semaglutide on heart failure outcomes in diabetes and chronic disease in the FLOW trial. J Am Coll Cardiol. 2024;84(17):1615\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"3241_CR36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman AM, et al. Effect of the glucagon-like peptide-1 receptor agonists Semaglutide and Liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022;145(8):575\u201385.","journal-title":"Circulation"},{"issue":"1","key":"3241_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/dom.15287","volume":"26","author":"S Sivalingam","year":"2024","unstructured":"Sivalingam S, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: a randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26(1):54\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"3241_CR38","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/STROKEAHA.121.037775","volume":"53","author":"WD Strain","year":"2022","unstructured":"Strain WD, et al. Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022;53(9):2749\u201357.","journal-title":"Stroke"},{"issue":"7","key":"3241_CR39","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/dom.14700","volume":"24","author":"S Verma","year":"2022","unstructured":"Verma S, et al. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022;24(7):1288\u201399.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"3241_CR40","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/dom.13698","volume":"21","author":"S Verma","year":"2019","unstructured":"Verma S, et al. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: a post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes Obes Metab. 2019;21(7):1745\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"3241_CR41","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1111\/dom.14160","volume":"22","author":"S Verma","year":"2020","unstructured":"Verma S, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487\u201392.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3241_CR42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13098-023-01195-7","volume":"15","author":"S Hu","year":"2023","unstructured":"Hu S, Su X, Fan G. Efficacy and tolerability of the subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis. Diabetol Metab Syndr. 2023;15(1):218.","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"3241_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","volume":"83","author":"W Wu","year":"2024","unstructured":"Wu W, et al. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis. Endocrine. 2024;83(3):571\u201384.","journal-title":"Endocrine"},{"key":"3241_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.695182","volume":"12","author":"P Zhong","year":"2021","unstructured":"Zhong P, et al. Efficacy and safety of subcutaneous and oral semaglutide administration in patients with type 2 diabetes: a meta-analysis. Front Pharmacol. 2021;12:695182.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3241_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40618-024-02459-3","volume":"48","author":"M Ala","year":"2025","unstructured":"Ala M, Moheb Aleaba M. The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression. J Endocrinol Invest. 2025;48(2):283\u201394.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"3241_CR46","doi-asserted-by":"publisher","first-page":"2239830","DOI":"10.1080\/07853890.2023.2239830","volume":"55","author":"T Patel","year":"2023","unstructured":"Patel T, et al. Comparative efficacy and safety profile of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Ann Med. 2023;55(2):2239830.","journal-title":"Ann Med"},{"issue":"1","key":"3241_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41366-024-01646-9","volume":"49","author":"AS Cleto","year":"2025","unstructured":"Cleto AS, et al. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Int J Obes. 2025;49(1):21\u201330.","journal-title":"Int J Obes"},{"issue":"3","key":"3241_CR48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/dom.13553","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21(3):499\u2013508.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3241_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10157","key":"3241_CR50","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"key":"3241_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082359","author":"S Roumeliotis","year":"2020","unstructured":"Roumeliotis S, Mallamaci F, Zoccali C. Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9082359.","journal-title":"J Clin Med"},{"key":"3241_CR52","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.001918","author":"SC Hung","year":"2015","unstructured":"Hung SC, et al. Volume overload and adverse outcomes in chronic kidney disease: clinical observational and animal studies. J Am Heart Assoc. 2015. https:\/\/doi.org\/10.1161\/JAHA.115.001918.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"3241_CR53","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ki.2013.336","volume":"85","author":"S-C Hung","year":"2014","unstructured":"Hung S-C, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int. 2014;85(3):703\u20139.","journal-title":"Kidney Int"},{"issue":"12","key":"3241_CR54","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1177\/039139880803101203","volume":"31","author":"M Cozzolino","year":"2008","unstructured":"Cozzolino M, Gallieni M, Brancaccio D. The mechanisms of hyperphosphatemia-induced vascular calcification. Int J Artif Organs. 2008;31(12):1002\u20133.","journal-title":"Int J Artif Organs"},{"key":"3241_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bone.2016.11.012","volume":"100","author":"S Yamada","year":"2017","unstructured":"Yamada S, Giachelli CM. Vascular calcification in CKD-MBD: roles for phosphate, FGF23, and Klotho. Bone. 2017;100:87\u201393.","journal-title":"Bone"},{"issue":"4","key":"3241_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pathophys.2018.04.003","volume":"25","author":"D Gabriel-Costa","year":"2018","unstructured":"Gabriel-Costa D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology. 2018;25(4):277\u201384.","journal-title":"Pathophysiology"},{"issue":"3","key":"3241_CR57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41581-025-00930-9","volume":"21","author":"R Kalyesubula","year":"2025","unstructured":"Kalyesubula R, Luyckx VA. Managing risk factors and early intervention for chronic kidney disease. Nat Rev Nephrol. 2025;21(3):149\u201350.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"3241_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.kisu.2017.07.003","volume":"7","author":"VA Luyckx","year":"2017","unstructured":"Luyckx VA, et al. Reducing major risk factors for chronic kidney disease. Kidney Int Suppl (2011). 2017;7(2):71\u201387.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"2","key":"3241_CR59","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487\u201393.","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"3241_CR60","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","volume":"43","author":"Association, A.D.","year":"2020","unstructured":"Association, A.D. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Supplement_1):S98\u2013110.","journal-title":"Diabetes Care"},{"issue":"7","key":"3241_CR61","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/dom.15058","volume":"25","author":"DK McGuire","year":"2023","unstructured":"McGuire DK, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023;25(7):1932\u201341.","journal-title":"Diabetes Obes Metab"},{"issue":"2_suppl","key":"3241_CR62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25\u201332.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"3241_CR63","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1161\/CIRCRESAHA.118.314487","volume":"124","author":"D Sun","year":"2019","unstructured":"Sun D, et al. Type 2 diabetes and hypertension: a study on bidirectional causality. Circ Res. 2019;124(6):930\u20137.","journal-title":"Circ Res"},{"issue":"1","key":"3241_CR64","doi-asserted-by":"publisher","first-page":"8936865","DOI":"10.1155\/2021\/8936865","volume":"2021","author":"S Rezaei","year":"2021","unstructured":"Rezaei S, et al. GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2021;2021(1):8936865.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"3241_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","author":"H Yao","year":"2024","unstructured":"Yao H, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024. https:\/\/doi.org\/10.1136\/bmj-2023-076410.","journal-title":"BMJ"},{"issue":"1","key":"3241_CR66","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/jrms.jrms_693_23","volume":"29","author":"L Yang","year":"2024","unstructured":"Yang L, et al. Effectiveness and safety of semaglutide in overweight\/obese adults with or without type 2 diabetes: a systematic review and meta-analysis. J Res Med Sci. 2024;29(1):60.","journal-title":"J Res Med Sci"},{"issue":"10","key":"3241_CR67","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCRESAHA.119.312617","volume":"124","author":"M Ouimet","year":"2019","unstructured":"Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport. Circ Res. 2019;124(10):1505\u201318.","journal-title":"Circ Res"},{"key":"3241_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/11.suppl_h.1","author":"NE Miller","year":"1990","unstructured":"Miller NE. HDL metabolism and its role in lipid transport. Eur Heart J. 1990. https:\/\/doi.org\/10.1093\/eurheartj\/11.suppl_h.1.","journal-title":"Eur Heart J"},{"issue":"2","key":"3241_CR69","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1042\/CS20080106","volume":"116","author":"F Tabet","year":"2009","unstructured":"Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond). 2009;116(2):87\u201398.","journal-title":"Clin Sci (Lond)"},{"issue":"25","key":"3241_CR70","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.2174\/0929867321666140414105530","volume":"21","author":"S Madahian","year":"2014","unstructured":"Madahian S, et al. Inflammation, high density lipoprotein and endothelium. Curr Med Chem. 2014;21(25):2902\u20139.","journal-title":"Curr Med Chem"},{"key":"3241_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2022.109397","volume":"730","author":"R Fadaei","year":"2022","unstructured":"Fadaei R, Davies SS. Oxidative modification of HDL by lipid aldehydes impacts HDL function. Arch Biochem Biophys. 2022;730:109397.","journal-title":"Arch Biochem Biophys"},{"key":"3241_CR72","doi-asserted-by":"crossref","unstructured":"Toth PP. Should we target HDL cholesterol level in lowering cardiovascular risk? Pol Arch Med Wewn. 2009;119(10): p.667-72.","DOI":"10.20452\/pamw.801"},{"key":"3241_CR73","doi-asserted-by":"crossref","unstructured":"Kjeldsen EW, JQ Thomassen  R Frikke-Schmidt. HDL cholesterol concentrations and risk of atherosclerotic\ncardiovascular disease \u2013 Insights from randomized clinical trials and human genetics. Biochimica et Biophysica Acta (BBA) -\nMolecular and Cell Biology of Lipids. 2022;1867(1): p.159063.","DOI":"10.1016\/j.bbalip.2021.159063"},{"key":"3241_CR74","unstructured":"Mach F et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular\nrisk. Eur Heart J. 2020;41(1): p.111-188."}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03241-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03241-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03241-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:04:24Z","timestamp":1762290264000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03241-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3241"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03241-8","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Formal ethics committee approval was not required for this study, as it involves the secondary analysis of publicly available, de-identified data from previously published clinical trials. All original trials included in our analysis have been documented to have adhered to the Good Clinical Practice guidelines and\/or the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1059"}}